CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 499 enrolled
Drug / intervention
rt-PAdrug
Likely dose
rt-PA 1.0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01827046
NCT01827046Phase 3Completed
CompareCT.gov

Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III

Johns Hopkins University·interventional·Posted Apr 9, 2013·Updated Sep 27, 2019

In Brief

A Phase 3 clinical trial evaluating rt-PA for Intracerebral Hemorrhage. Completed, enrolled 499 participants across 84 sites in 9 countries.

Detailed Summary

A phase III, randomized, case-controlled, open-label, 500-subject clinical trial of minimally invasive surgery plus rt-PA in the treatment of intracerebral hemorrhage (ICH).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntracerebral Hemorrhage
CountriesAustralia, Canada, China, Germany, Hungary, Israel, Spain, United Kingdom, United States
CollaboratorsNational Institute of Neurological Disorders and Stroke (NINDS), Genentech, Inc., Emissary International LLC

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 9, 2013
Enrollment StartDec 30, 2013
Primary CompletionSep 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 13.2 years ago

Interventions

rt-PAdrug

Up to 9 doses of 1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.